she characterized the important posttranslational modifications of adiponectin, an anti-diabetic, anti-inflammatory, anti-atherosclotic, anti-cancer and hepatoprotective hormone. Her work on adiponectin has been cited over 8000 times.

she carried out independent research on Biomarker discoveries using “Omics” approaches and identified a series of novel biomarkers, such as lipocalin-2, fatty acid-binding protein 4, angiopoietin-like 4, FGF21 and SIRT1, which represent promising “druggale” targets in ageing-related cardiovascular, metabolic and cancer diseases.

Her current research is focusing on a number of “druggale” targets in ageing-related cardiovascular, metabolic and cancer diseases. Her group is performing molecular, cellular, pharmacological studies in both animal and human subjects to explore different approaches of intervention, largely based on the druggable biomolecules adiponectin, lipocalin-2 and SIRT1. Prof Wang has published over 200 journal articles/book chapters/invited reviews/commentaries, and is among the top 1% highly cited scientist with an H-index of 70.